| Literature DB >> 24155853 |
Manuel J Carvajal1, Kevin A Clauson, Jennifer Gershman, Hyla H Polen.
Abstract
OBJECTIVE: To explore knowledge and use of drug information resources by pharmacists and identify patterns influenced by gender and age-group classification.Entities:
Keywords: Age Factors; Drug Information Services; Pharmacists; Sex Factors; United States
Year: 2013 PMID: 24155853 PMCID: PMC3798172 DOI: 10.4321/s1886-36552013000200003
Source DB: PubMed Journal: Pharm Pract (Granada) ISSN: 1885-642X
Characteristics of responding pharmacists, percentages and standard deviations.
| Demographic Characteristic | Gender | Age Group | ||
|---|---|---|---|---|
| Both | 50 Years | Older than | ||
| Observations (n) | Both genders | 114 | 59 | 55 |
| Male | 64 | 21 | 43 | |
| Female | 50 | 38 | 12 | |
| Non-Hispanic White (%) | Both genders | 0.87 | 0.92§ | 0.82§ |
| Male | 0.83§ | 0.90 | 0.79 | |
| Female | 0.92§ | 0.92 | 0.92 | |
| Pharm.D. or Ph.D. (%) | Both genders | 0.24 | 0.37* | 0.09* |
| Male | 0.16‡ | 0.29 | 0.09 | |
| Female | 0.34‡ | 0.42 | 0.08 | |
| Primary work setting: | Both genders | 0.34 | 0.36 | 0.33 |
| Male | 0.36 | 0.38 | 0.35 | |
| Female | 0.32 | 0.34 | 0.25 | |
| Professional experience (years) | Both genders | 24.2 | 15.5* | 33.4* |
| Male | 29.5* | 19.4 | 34.4 | |
| Female | 17.4* | 13.4 | 30.2 | |
| Average work week (hours) | Both genders | 35.8 | 36.1 | 35.5 |
| Male | 36.2 | 36.9 | 35.9 | |
| Female | 35.3 | 35.6 | 34.1 | |
| *Percentages/means significantly different from each other
(p < 0.01). | ||||
Pharmacists' use and perception regarding drug information references
| Response | Gender | Age Group | ||
|---|---|---|---|---|
| Both | 50 Years | Older than | ||
| The most frequently used DI resource in my pharmacy is electronic | Both genders | 0.71 | 0.78† | 0.64† |
| Male | 0.59* | 0.67 | 0.56 | |
| Female | 0.86* | 0.84 | 0.92 | |
| There are sufficient print references in my pharmacy to answer DI questions if electronic resources are not operational | Both genders | 0.88 | 0.86 | 0.89 |
| Male | 0.91 | 0.95 | 0.88 | |
| Female | 0.84 | 0.82 | 0.92 | |
| Percentage certainty that I know which DI resource(s) must be maintained in my pharmacy in compliance with laws in my state | Both genders | 66.1 | 57.0* | 75.9* |
| Male | 71.7† | 64.0 | 75.5 | |
| Female | 59.0† | 53.2 | 77.5 | |
| Percentage certainty that I know which DI resources must be maintained for all pharmacy settings and specialties to be in compliance with laws in my state | Both genders | 54.9 | 45.0* | 65.5* |
| Male | 60.5† | 50.2 | 65.6 | |
| Female | 47.7† | 42.1 | 65.4 | |
| My pharmacy has a formal mechanism in place to keep DI resources current | Both genders | 0.52 | 0.48 | 0.56 |
| Male | 0.52 | 0.38 | 0.58 | |
| Female | 0.52 | 0.53 | 0.50 | |
| Electronic resources should be allowed to satisfy all legal requirements for DI resources kept in a pharmacy | Both genders | 0.54 | 0.52 | 0.54 |
| Male | 0.52 | 0.67 | 0.54 | |
| Female | 0.52 | 0.45 | 0.58 | |
| *Percentages/means significantly different from each other
(p <0.01). | ||||
Top three question types prompting use of a drug information reference, by gender and age group.
| Gender | Age Group | |||||
|---|---|---|---|---|---|---|
| Both Age Groups | 50 Years | Older than | ||||
| Both genders | Adverse drug reactions and side effects | (69.3%) | Dosing | (74.6%) | Adverse drug reactions and side effects | (78.2%) |
| Dosing | (63.2%) | Adverse drug reactions and side effects | (61.0%) | Compatibility and stability | (54.5%) | |
| Compatibility and stability | (55.3%) | Compatibility and stability | (55.9%) | Interactions | (52.7%) | |
| Male | Adverse drug reactions and side effects | (70.3%) | Dosing | (71.4%) | Adverse drug reactions and side effects | (76.7%) |
| Dosing | (59.4%) | Adverse drug reactions and side effects | (57.1%) | Dosing | (53.5%) | |
| Compatibility and stability | (50.0%) | Compatibility and stability | (47.6%) | Compatibility and stability | (51.2%) | |
| Female | Adverse drug reactions and side effects | (68.0%) | Dosing | (76.3%) | Adverse drug reactions and side effects | (83.3%) |
| Dosing | (68.0%) | Adverse drug reactions and side effects | (63.2%) | Interactions | (75.0%) | |
| Compatibility and stability | (62.0%) | Compatibility and stability | (60.5%) | Compatibility and stability | (66.7%) | |
Top two drug information resources used by pharmacists, by type of question encountered, gender, and age group.
| Type of | Gender | Age Group | |||||
|---|---|---|---|---|---|---|---|
| Both Age Groups | 50 Years | Older than | |||||
| Most Often | Both genders | Micromedex | (24.6%) | Micromedex | (23.7%) | Micromedex | (25.5%) |
| Facts & Comparisons | (16.7%) | Lexi-Comp Online | (18.6%) | Facts & Comparisons | (21.8%) | ||
| Male | Micromedex | (26.6%) | Micromedex | (28.6%) | Micromedex | (25.6%) | |
| Facts & Comparisons | (20.3%) | Facts & Comparisons | (14.3%) | Facts & Comparisons | (23.3%) | ||
| Female | Lexi-Comp Online | (26.0%) | Lexi-Comp Online | (26.3%) | Lexi-Comp Online | (25.0%) | |
| Micromedex | (22.0%) | Micromedex | (21.1%) | Clinical Pharmacology | (25.0%) | ||
| Adverse Drug Reactions and Side Effects | Both | Micromedex | (26.3%) | Micromedex | (28.8%) | Facts & Comparisons | (23.6%) |
| Facts & Comparisons | (16.7%) | Lexi-Comp Online | (18.6%) | Micromedex | (23.6%) | ||
| Male | Micromedex | (31.2%) | Micromedex | (42.9%) | Facts & Comparisons | (25.6%) | |
| Facts & Comparisons | (23.4%) | Facts & Comparisons | (19.0%) | Micromedex | (25.6%) | ||
| Female | Lexi-Comp Online | (26.0%) | Lexi-Comp Online | (26.3%) | Clinical Pharmacology | (25.0%) | |
| Micromedex | (20.0%) | Micromedex | (21.1%) | Lexi-Comp Online | (25.0%) | ||
| Compatibility | Both | Handbook on Inject. Drugs | (38.6%) | Handbook on Inject. Drugs | (35.6%) | Handbook on Inject. Drugs | (41.8%) |
| Micromedex | (15.8%) | Micromedex | (16.9%) | Micromedex | (14.5%) | ||
| Male | Handbook on Inject. Drugs | (45.3%) | Handbook on Inject. Drugs | (42.9%) | Handbook on Inject. Drugs | (46.5%) | |
| Micromedex | (12.5%) | Micromedex | (14.3%) | Facts & Comparisons | (11.6%) | ||
| Female | Handbook on Inject. Drugs | (30.0%) | Handbook on Inject. Drugs | (31.6%) | Handbook on Inject. Drugs | (25.0%) | |
| Micromedex | (20.0%) | Micromedex | (18.4%) | Micromedex | (25.0%) | ||
| Dietary | Both | NMCD | (25.4%) | NMCD | (32.2%) | NMCD | (18.2%) |
| RevNatProd | (14.9%) | RevNatProd | (16.9%) | No response | (18.2%) | ||
| Male | NMCD | (20.3%) | NMCD | (28.6%) | No response | (20.9%) | |
| No response | (18.8%) | RevNatProd | (19.0%) | Micromedex | (18.6%) | ||
| Female | NMCD | (32.0%) | NMCD | (34.2%) | NMCD | (25.0%) | |
| RevNatProd | (14.0%) | RevNatProd | (15.8%) | GlobalRph.com | (16.7%) | ||
| Dosing | Both | Micromedex | (21.9%) | Micromedex | (25.4%) | Facts & Comparisons | (18.2%) |
| Facts & Comparisons | (15.8%) | Lexi-Comp Online | (16.9%) | Micromedex | (18.2%) | ||
| Male | Micromedex | (25.0%) | Micromedex | (33.3%) | Facts & Comparisons | (20.9%) | |
| Facts & Comparisons | (18.8%) | Facts & Comparisons | (14.3%) | Micromedex | (20.9%) | ||
| Female | Lexi-Comp Online | (26.0%) | Lexi-Comp Online | (26.3%) | Lexi-Comp Online | (25.0%) | |
| Micromedex | (18.0%) | Micromedex | (21.1%) | Clinical Pharmacology | (16.7%) | ||
| Indications | Both | Micromedex | (26.3%) | Micromedex | (28.8%) | Micromedex | (23.6%) |
| Clinical Pharmacology | (14.0%) | Clinical Pharmacology | (13.6%) | Clinical Pharmacology | (14.5%) | ||
| Male | Micromedex | (29.7%) | Micromedex | (38.1%) | Micromedex | (25.6%) | |
| Facts & Comparisons | (14.1%) | Epocrates Rx Premium | (14.3%) | Facts & Comparisons | (16.3%) | ||
| Female | Lexi-Comp Online | (22.0%) | Micromedex | (23.7%) | Clinical Pharmacology | (25.0%) | |
| Micromedex | (22.0%) | Lexi-Comp Online | (21.1%) | Lexi-Comp Online | (25.0%) | ||